君实生物-U
(688180)
| 流通市值：229.92亿 | | | 总市值：297.09亿 |
| 流通股本：7.63亿 | | | 总股本：9.86亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 380,804,271.07 | 1,502,549,915.75 | 986,457,567.67 | 669,702,667.07 |
| 营业收入 | 380,804,271.07 | 1,502,549,915.75 | 986,457,567.67 | 669,702,667.07 |
| 二、营业总成本 | 703,379,531.6 | 3,811,859,509.4 | 2,479,371,840.85 | 1,772,814,913.95 |
| 营业成本 | 108,094,203.03 | 540,976,390.72 | 336,845,004.3 | 252,155,636.11 |
| 税金及附加 | 5,643,377.09 | 19,704,320.97 | 13,435,038.4 | 8,775,955.55 |
| 销售费用 | 191,592,867.84 | 844,355,927 | 554,408,514.86 | 373,126,850.39 |
| 管理费用 | 123,309,563.52 | 536,439,566.54 | 359,400,187.23 | 232,304,096.15 |
| 研发费用 | 276,292,124.92 | 1,937,469,544.84 | 1,270,626,649.07 | 948,598,826.58 |
| 财务费用 | -1,552,604.8 | -67,086,240.67 | -55,343,553.01 | -42,146,450.83 |
| 其中:利息费用 | 11,684,234.17 | 23,006,975.29 | 19,975,951.59 | 12,720,671.54 |
| 其中:利息收入 | 13,959,616.53 | 99,426,230.82 | 77,612,046.32 | 55,026,734.29 |
| 加:公允价值变动收益 | -1,154,733.64 | -149,177,392.25 | -45,848,211.85 | -27,766,182.96 |
| 加:投资收益 | -7,397,349.03 | 73,990,355.55 | -44,866,462.66 | -28,070,638.56 |
| 资产处置收益 | 23,722,664.29 | 29,406,432.28 | 600,424.64 | 510,895.52 |
| 资产减值损失(新) | 6,318,900.98 | -126,313,501.28 | -35,245,743.13 | -36,357,648.87 |
| 信用减值损失(新) | 2,695,299.66 | -23,483,189.23 | -1,113,612.12 | -1,122,091.9 |
| 其他收益 | 5,554,844.4 | 47,444,534.82 | 39,025,160.64 | 33,625,928.15 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -292,835,633.87 | -2,457,442,353.76 | -1,580,362,717.66 | -1,162,291,985.5 |
| 加:营业外收入 | 17,162.5 | 3,913,286.2 | 3,928,909.1 | 3,611,791.11 |
| 减:营业外支出 | 3,730,898.82 | 38,165,533.03 | 31,081,561.88 | 18,144,094.93 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -296,549,370.19 | -2,491,694,600.59 | -1,607,515,370.44 | -1,176,824,289.32 |
| 减:所得税费用 | 3,098,595.27 | 43,994,697.26 | -52,386,479.09 | -50,494,762.83 |
| 六、净利润 | -299,647,965.46 | -2,535,689,297.85 | -1,555,128,891.35 | -1,126,329,526.49 |
| 持续经营净利润 | -299,647,965.46 | -2,535,689,297.85 | -1,555,128,891.35 | -1,126,329,526.49 |
| 归属于母公司股东的净利润 | -283,029,082.76 | -2,283,431,860.25 | -1,406,818,402.73 | -997,412,406.48 |
| 少数股东损益 | -16,618,882.7 | -252,257,437.6 | -148,310,488.62 | -128,917,120.01 |
| (一)基本每股收益 | -0.29 | -2.32 | -1.43 | -1.01 |
| (二)稀释每股收益 | -0.29 | -2.32 | -1.43 | -1.01 |
| 八、其他综合收益 | 852,568.88 | -73,658,461.53 | -50,732,766.43 | -38,178,177.32 |
| 归属于母公司股东的其他综合收益 | 852,568.88 | -73,658,461.53 | -50,732,766.43 | -38,178,177.32 |
| 九、综合收益总额 | -298,795,396.58 | -2,609,347,759.38 | -1,605,861,657.78 | -1,164,507,703.81 |
| 归属于母公司股东的综合收益总额 | -282,176,513.88 | -2,357,090,321.78 | -1,457,551,169.16 | -1,035,590,583.8 |
| 归属于少数股东的综合收益总额 | -16,618,882.7 | -252,257,437.6 | -148,310,488.62 | -128,917,120.01 |
| 公告日期 | 2024-04-30 | 2024-03-29 | 2023-10-28 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |